Rheumatoid arthritis and atherosclerosis: Could common pathogenesis translate into common therapies?

Hellenic Journal of Cardiology

Volumn 56, Issue September-October, 2015, Pages 414-417

  Lazaros, George ^a   Tousoulis, Dimitrios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

BDMARDs; Cardiovascular diseases; Rheumatoid arthritis; Safety

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; INFLIXIMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ARTERIAL STIFFNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; HUMAN; INFLAMMATION; MOLECULAR PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; COMORBIDITY; FEMALE; MALE;

ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; COMORBIDITY; FEMALE; HUMANS; MALE;

EID: 84943160855     PISSN: 11099666     EISSN: 22415955     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Toutouzas K, Sfikakis PP, Karanasos A, et al. Myocardial ischaemia without obstructive coronary artery disease in rheumatoid arthritis: hypothesis-generating insights from a cross-sectional study. Rheumatology (Oxford). 2013; 52: 76-80.
2. Gerosa M, De Angelis V, Riboldi P, Meroni PL. Rheumatoid arthritis: a female challenge. Womens Health (Lond Engl). 2008; 4: 195-201.
3. Brooks PM. The burden of musculoskeletal disease--a global perspective. Clin Rheumatol. 2006; 25: 778-781.
4. Dhawan SS, Quyyumi AA. Rheumatoid arthritis and cardiovascular disease. Curr Atheroscler Rep. 2008; 10: 128-133.
5. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford). 2012; 51 Suppl 5: v38-47.
6. Richards JS, Dowell SM, Quinones ME, Kerr GS. How to use biologic agents in patients with rheumatoid arthritis who have comorbid disease. BMJ. 2015; 351: h3658. doi: 10.1136/ bmj.h3658.
7. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014; 73: 492-509.
8. Woodrick RS, Ruderman EM. Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol. 2011; 7: 639-652.
9. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012; 64: 625-639.
10. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011; 70: 576-582.
11. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340: 115-126.
12. Ayyildiz YO, Vural MG, Efe TH, et al. Effect of long-term TNF-α inhibition with infliximab on left ventricular torsion in patients with rheumatoid arthritis. Hellenic J Cardiol. 2015; 56: 406-413.
13. Ikonomidis I, Lekakis JP, Nikolaou M, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation. 2008; 117: 2662-2669.
14. Ikonomidis I, Tzortzis S, Andreadou I, et al. Increased bene fit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging. 2014; 7: 619-628.
15. Lazaros G, Vlachopoulos C, Stefanadis C. Idiopathic recurrent pericarditis: searching for Ariadne's thread. Hellenic J Cardiol. 2009; 50: 345-351.
16. Imazio M, Lazaros G, Brucato A, Gaita F. Recurrent pericarditis: new and emerging therapeutic options. Nat Rev Cardiol. 2015 Aug 11. doi:10.1038/nrcardio.2015.115. [Epub ahead of print].
17. Lazaros G, Imazio M, Brucato A, et al. Anakinra: an emerging option for refractory idiopathic recurrent pericarditis: a systematic review of published evidence. J CardiovascMed (Hagerstown). 2015; Jun 18. [Epub ahead of print]
18. Lazaros G, Vasileiou P, Koutsianas C, et al. Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases. Ann Rheum Dis. 2014; 73: 2215-2217.